36.8 F
New York
Sunday, January 17, 2021

CytoDyn Inc (OTCMKTS:CYDY) Moves Above The Trading Range: Buy, Sell, or Hold?

Must read

CytoDyn Inc (OTCMKTS:CYDY) Hits 4-Month High As Covid-19 Fear Grows

The coronavirus pandemic unleashed chaos all over the world and also in the markets, however, some biotech companies working on treatments for...

Alpine 4 Technologies Ltd (OTCMKTS:ALPP) Hits New High as Market Share Grows

Monday was not a particularly great time in the markets owing to renewed fears about COVID 19, but there were some stocks...

Grayscale Ethereum Trust (ETH) (OTCMKTS:ETHE) Jumps On Crypto Hype: Is it Sustainable?

The massive rally in the cryptocurrency space has been one of the biggest stories of the year in investment circles.

Tesoro Enterprises, Inc. (OTCMKTS:TSNP) Turns Volatile in Mid-December

Over the course of the past month, many companies have seen their stocks make substantial gains but the gains made by the...

Over the course of the year so far many companies have come into focus among investors due to its work on products meant for tackling the coronavirus pandemic and one such company is CytoDyn Inc (OTCMKTS:CYDY).

Over the course of the past week the CytoDyn stock has come back into focus among investors following a major development.

Key Developments

The stock has rallied by as much as 50% over the course of the past week and it could be worthwhile for investors to perhaps take a closer look at the latest news.

The company’s product leronlimab, which is also being tested as a treatment for COVID 19 patients, is at the centre of the latest developments.

Last Thursday, the company that it successfully enrolled the very first patient for the Phase 2 study of leronlimab as a potential treatment of NASH (nonalcoholic steatohepatitis). NASH is a well known and chronic condition of the liver. The preclinical study that has been conducted into leronlimab has shown that it could help in the treatment of NAFLD (nonalcoholic fatty liver disease).

That is a significant update considering the fact that NASH is often preceded by NASH in patients. This particular update may have been the main reason behind the renewed interest in the stock this past week.

The possibility of using leronlimab for treating patients suffering from coronavirus infection has also proven to be a major trigger for the stock. Over the course of 2020 so far, the stock has rallied by as much as 147% and that is particularly notable since, during the same period, the rest of the industry has recorded a 2% decline.

The results of the Phase 2 study into the possibility of leronlimab as a treatment for COVID 19 produced positive results as well. In this regard, it is also necessary to point out that CytoDyn is also trying to develop leronlimab as a potential treatment for different forms of cancer.

Disclaimer: We hold no position in CYDY stock.

Latest article

Ozop Energy Solutions Inc (OTCMKTS:OZSC) Remains Volatile: Stock in Focus

Those who are looking to discover stocks that may have made big moves over the course of the past week could consider...

Data Storage Corp (OTCMKTS:DTST) Gets Sudden Attention: What’s The Buzz?

One of the stocks to have made significant gains this week was that of Data Storage Corp (OTCMKTS:DTST). The Data Storage Corporation...

A Closer Looks at American Battery Metals Corp (OTCMKTS:ABML) Developments

American Battery Metals Corp (OTCMKTS:ABML) is one of the stocks to have been in focus among investors over the course of the...

Why is Grayscale Ethereum Trust (ETH) (OTCMKTS:ETHE) In a Bearish Trend?

The Bitcoin rally over the past weeks has taken the crypto space by storm. However, it should not be forgotten that Ethereum,...

Curaleaf Holdings (OTCQX:CURLF) Continues to Hit New Highs: Next Move?

The cannabis sector has had its ups and downs over the last year, but there are certain stocks that are almost always...